chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Ill-Fever of 102; diarrhea; vomiting; Break through bleeding; Ill-Fever of 102; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 19Apr2021 09:15 (Lot number: ER8731) at the age of 35 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (Pfizer,, lot_number #EN8733,, administration date=29Mar2021,, time=09:15, dose_number=1,, Leftarm), administration date: 29Mar2021, when the patient was 35 years old, for COVID-19 IMMUNIZATION, reaction(s): "Break through bleeding", "Cramping". The following information was reported: PYREXIA (non-serious), ILLNESS (non-serious), outcome "recovered with sequelae" and all described as "Ill-Fever of 102"; DIARRHOEA (non-serious), outcome "recovered with sequelae", described as "diarrhea"; VOMITING (non-serious), outcome "recovered with sequelae", described as "vomiting"; INTERMENSTRUAL BLEEDING (non-serious), outcome "recovered with sequelae", described as "Break through bleeding". The events "ill-fever of 102", "diarrhea", "vomiting", "break through bleeding" and "ill-fever of 102" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of pyrexia, diarrhoea, vomiting, intermenstrual bleeding, illness.  Additional information: I had break through bleeding and cramping within 24 hours of 1 dose which lead to heavy bleeding for the next 4 weeks up to the time of dose 2. I continued to cramp and bleed for 2 more weeks. I also became extremely ill-fever of 102, diarrhea and vomiting for 48 hours after second dose. I continue to have breakthrough bleeding randomly between menstrual cycles and I'm having much worse menstrual cycle side effects examples debilitating cramps nausea and diarrhea that I did not have prior to being vaccinated with Pfizer COVID- 19 vaccine. No other vaccine in four weeks. No covid prior vaccination and No covid tested post vaccination. No Known allergies.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101449345 similar report from same reporter
tired; can throw up anytime; nauseated; pain in his arm of injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain in his arm of injection), FATIGUE (tired), VOMITING (can throw up anytime) and NAUSEA (nauseated) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination.     Concomitant products included LISINOPRIL, VENLAFAXINE HYDROCHLORIDE (FLAVIX), SIMVASTATIN, INSULIN GLARGINE (LANTUS), GABAPENTIN and ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, the patient experienced VACCINATION SITE PAIN (pain in his arm of injection). On 13-Mar-2021, the patient experienced FATIGUE (tired), VOMITING (can throw up anytime) and NAUSEA (nauseated). At the time of the report, VACCINATION SITE PAIN (pain in his arm of injection), FATIGUE (tired), VOMITING (can throw up anytime) and NAUSEA (nauseated) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment taken by the patient.
Pt. experienced vomiting and headache approx. 3 hours after each dose of Vivotif.  Pt. states no pills in vomit.  Pt. completed course of vaccine.  None of these episodes were reported at the time.
Persistent chest infection, difficulty breathing, (started two weeks after vaccine), given antibiotic (refused to take), 3 weeks of orange mass of stringy mucus (very unusual and severe), symptoms almost exclusively left side, steroid inhalants, inhaled iodine spray (seemed to help significantly)
Woke up yesterday to large red rash on arm.  Itchy and warm to touch. It is about 6 inches wide. Persisting today.
This is a spontaneous report from a contactable medical assistant who was calling from pediatrician's office on behalf of the physician, obtained via a Non Clinical Study Program (Pfizer Customer Service). A 18 months old male patient received fourth single dose PREVNAR 13 (lot H83179, expiration date 30Sep2015) on 11Sep2014, in the right thigh, at 0.5 ml single. Concomitant vaccines included: HIB vaccine in left thigh on 11Sep2014 at 0.5 ml and DTAP in left thigh on 11Sep2014 at 0.5 ml. Medical history was not provided. The reporter stated that the vaccine caused the patient cellulitis on an unspecified date in Sep2014. The reporter stated they went to the ER on Saturday over the weekend and in the ER they diagnosed him with the staph infection and he came in today and our doctor actually said that it was cellulitis. The patient did get some blood work when he went to the ER over the weekend. The patient came to the clinic for follow up on 17Sep2014. The patient was given the first dose of PREVNAR 13 on 23Apr2013, second dose on 18Jun2013 and third dose on 20Aug2013. There was no known reaction in the past. The patient was recovering from cellulitis at the time of report.
Tinnitus; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 09Mar2022 at 13:00 as dose 3 (booster), single (Lot number: FK9895) at the age of 62 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (product: COVID 19,, prev_dose_brand: Pfizer,, prev_dose_lot_number: ER8735,, prev_dose_administration_date: 06A, pr2021, prev_dose_dose_number: 2,, prev_dose_vaccine_location: Left, arm), administration date: 06Apr2021, when the patient was 61-year-old, for COVID-19 immunization; BNT162b2 (prev_dose_product: COVID 19,, prev_dose_brand: Pfizer,, Lot number: EP6955,, prev dose administration date:14M, ar2021, prev_dose_dose_number: 1,, prev_dose_vaccine_location: Left, arm}]), administration date: 14Mar2021, when the patient was 61-year-old, for COVID-19 immunization, reaction(s): "Major Vertigo issue". The following information was reported: TINNITUS (non-serious) with onset Mar2022, outcome "not recovered". The event "tinnitus" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of tinnitus.  Additional information: It was reported that a week after 1st dose patient experienced major vertigo issues for no apparent reason. Patient went to ER to ensure she wasn't having a stroke. Within a week after her 3rd Dose, she has been experiencing Tinnitus in both ears, but primarily in her left (loudest there) 24/7. Patient had no Covid prior vaccination. Patient had tested Covid post vaccination. Known allergies: No.  No follow-up attempts are possible. No further information is expected.
Fatigue, unable to do normal exercise routine, less muscle strength and endurance, short of breath more easily when exercising, difficulty sleeping,  wake up and not able to fall back asleep, vaginal bleeding and then abnormal yellow green vaginal discharge
17 year old patient got both dose of vaccine; This spontaneous case was reported by a physician and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old patient got both dose of vaccine) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033C21A and 033C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old patient got both dose of vaccine). On 22-May-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old patient got both dose of vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. Treatment medications were unknown.  Patient has not reported any symptoms.   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Dose 2 details recieved
I received the Moderna Bivalent booster for COVID-19 on 10/16/2022. On 11/19/2022, I developed a cough and nasal congestion in the afternoon. On 11/20/2022, I took a home antigen test and got a negative result. The symptoms remained about the same, though I also developed some chest congestion. On the evening of 11/21/2022, I felt more fatigued, though it wasn't major. I still had cough and congestion at this point. I took another home antigen test on 11/22/2022 and got a positive result. I then self-isolated and began masking while at home to protect my children. I had a telehealth visit with my doctor that day, and I was prescribed PAXLOVID. I began taking PAXLOVID on 11/23/2022. In addition to the aforementioned symptoms, I also had headaches. I took some ibuprofen for the headache and MUCINEX to help with the cough and congestion. The MUCINEX and ibuprofen helped with my symptoms, and I felt better afterwards. I took another home antigen test on 11/27/2022 and got another positive result. At the time of this writing, I feel fine and am able to work from home. My only complaint at this point is that I have a bitter aftertaste from the Paxlovid and a loss of my sense of smell.
with in 12 hrs i awoke to throwing up and dry heaving for two days migraine that last all6 days ,i broke out with a rash that resembled a a bad sunburn, that extended from elbow all the way to my scalp, dizziness,and i ached all over had low grade fever and chills that lasted 3 days my mouth went very dry
On March 15 I started experiencing pain in both hips as I was walking.  This pain continued and a few days later I started to experience pain in my lower back in addition to the pain in my hips.  It was very hard to walk and if I went too far or long I had to stop and wait for the pain to lessen.  The pain had lessened but is still present.  on about March 20/21 I noticed a blister on the index finger of my right hand.  A rash showed up on my left arm in the area of my wrist on March 23.  It is now March 25 and the rash all over my whole body.  It itches and at times is painful.
Patient received vaccine on Weds 10/27.  On thursday morning, patient reprted feeling some chest tightness.  On friday, patient had a small rash on upper chest which was itchy.  On friday she also reports a bulls-eye red rash near the injection site.  The rash is about 4-5 inches in diameter, is red, warm, and raised.  It is very slightly tender, but not itchy.  Today, on Saturday, the rash near injection site on left arm remains more or less the same.  The rash on upper chest is less itchy, but patient has been using Triamcinolone cream 0.1% on it (prescribed for another rash previously).
Sore arm, chest pain, fatigue, nausea, headache, fever, vomiting, chills (shaking)
Allergic reaction:  severe itching, throbbed and swelling despite icing and anti-itch creams.  Headaches.
After 10 min receiving the second dose I passed out during observation at the vaccination site, was rushed to the ER.  They monitored me, gave me fluids and performed an EKG.
Tested positive for covid; Tested positive for covid; congestion; sore throat; lost of smell and taste; lost of smell and taste; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63 year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm left, administration date 21Oct2021 (Lot number: FH8020) at the age of 62 years as dose 3 (booster), single, administered in arm left, administration date 19Feb2021 (Lot number: EL9266) as dose 2, single and administered in arm left, administration date 29Jan2021 (Lot number: EL9269) as dose 1, single for covid-19 immunisation. Relevant medical history included: "HBP" (unspecified if ongoing). None of known allergies. No covid prior vaccination. Concomitant medication(s) included: ACCURETIC; LIPITOR; TOPROL XL; ASA. No other vaccine in four weeks.  The following information was reported: IMMUNISATION (medically significant) with onset 21Oct2021, outcome "unknown", described as "Booster"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 10Jan2022, outcome "unknown" and all described as "Tested positive for covid"; NASAL CONGESTION (non-serious) with onset 07Jan2022 15:00, outcome "recovering", described as "congestion"; OROPHARYNGEAL PAIN (non-serious) with onset 07Jan2022 15:00, outcome "recovering", described as "sore throat"; ANOSMIA (non-serious), AGEUSIA (non-serious) all with onset 07Jan2022 15:00, outcome "recovering" and all described as "lost of smell and taste". The patient underwent the following laboratory tests and procedures: saliva analysis: (11Jan2022) pending, notes: Other; sars-cov-2 test: (10Jan2022) positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of nasal congestion, oropharyngeal pain, anosmia, ageusia.  No follow-up attempts are possible. No further information is expected.
Dose Number: 5; Dose Number: 5; COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Laryngopharyngeal reflux" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "not recovered" and all described as "COVID-19 Treatment"; OFF LABEL USE (medically significant), IMMUNISATION (medically significant), outcome "unknown" and all described as "Dose Number: 5". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2022) Positive, notes: Positive tests and symptoms worsening after negative test on day after treatment ended; (20Jun2022) Negative, notes: Positive tests and symptoms worsening after negative test on day after treatment ended. Therapeutic measures were taken as a result of drug ineffective, covid-19. Patient had not received any Other medication in 2 weeks. Patient had received anti-viral treatment from 16Jun2022 to 20Jun2022 for the treatment of COVID-19. Positive tests and symptoms worsening after negative test on day after treatment ended on 16Jun2022. Patient had no known allergies. The patient had not received any other medications and products within 2 weeks of starting COVID-19 treatment. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
fever of 102.5F the morning after covid vaccine #2 given.  Also had chest pain and shortness of breath.  Tylenol given which helped with symptoms.  The following day, all symptoms had resolved.
After 12 min of injection my ears were ringing and I felt weird, asked to lay down checked my BP which was elevated for me 160/90.  Injection site swelled approx 20 cm x 15cm red hot swollen and itchy for 10 days. In those 10 days I had multiple unexplained ringing of the ears with same funny feeling and checked my BP which was low 105/56. Those episodes carried on for the length of 14 days after vaccine #1 and only lasted for 2-3 min at a time.
Nausea; Dizziness; light headedness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), DIZZINESS (light headedness) and NAUSEA (Nausea) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 05-Feb-2021, the patient experienced DIZZINESS (Dizziness) and DIZZINESS (light headedness). On an unknown date, the patient experienced NAUSEA (Nausea). At the time of the report, DIZZINESS (Dizziness), DIZZINESS (light headedness) and NAUSEA (Nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.    No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 24-Mar-2021: No specific follow-up information recorded.
Patient became dizzy and fainted a few minutes after getting shot. Pt got sweaty, stated nauseous and said he felt like his hands felt crampy. Patient sat for about 10 to 15 minutes and stated feeling fine.
LITTLE DIZZINESS; WRIST ACHE; BIG WAVE OF NAUSEA; BIG FATIGUE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the patient experienced little dizziness, wrist ache, big wave of nausea, and big fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from little dizziness, wrist ache, big wave of nausea, and big fatigue. This report was non-serious.
3 days later the 2nd dose started getting big blisters spots; This case was reported by a consumer via interactive digital media and described the occurrence of blister in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In April 2022, the patient received the 2nd dose of Shingrix. In April 2022, an unknown time after receiving Shingrix, the patient experienced blister. On an unknown date, the outcome of the blister was unknown.   It was unknown if the reporter considered the blister to be related to Shingrix.     Additional Information: GSK Receipt Date: 7-May-2022 Reporter's Comment: The patient self-reported this case via interactive digital media. The patient received dose of Shingrix vaccine 10 days ago and 3 days later he/she started getting big blisters spots all over his/her right side. The patient asked could he/she get Shingles from the vaccine. Additional supportive information: The follow-up would not possible, as no contact, details were available.
Pt walked to waiting area to wait after vaccination and begin to have syncope event while seated within 5 minutes. Patient came to within a few minutes and was offered water. Patient remained seated for next 10 minutes and left when he felt better.
This spontaneous report as received from a nurse refers to multiple unspecified patients of unknown ages and genders. On unknown dates, the patients were administered an unknown number of doses of VARIVAX (lot # M025867, expiry date: 24-MAY-2018; lot # M023382, expiry date: 11-MAY-2018) that was exposed to 29.6 F for 7 hours 45 minutes. No adverse effects were reported. The outcome of the events was unknown. This is one of the several reports received from the same reporter. Additional information has been requested.
Severe chills, fever, rapid heart beat, joint pain, sick to stomach, extreme headache. So sick could not call for help. Symptoms lasted for 12 hours.
Started to feel stiffness approximately 3 hours after injection and noticed large area of swelling at and around injection site.
reported  chest heaviness SOB ,  believed  it was an asthma attack.12/28 was seen by cardiologist and sent home on 12/29 was seen by cardiologist , had an echo    and sent home on steroid
received their first dose / in 2019 and its been over a year and they haven't yet received dose 2; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 31-year-old female patient who received HAV (Havrix 1440) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Havrix 1440 (received 1st dose in 2019, Batch number- 2AD47 and expiration date- 31st January 2020).   On an unknown date, the patient received the 2nd dose of Havrix 1440 and Havrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Havrix 1440 and Havrix Pre-Filled Syringe Device, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive the 2nd dose of Havrix 1440 as per the vaccination schedule, which led to incomplete course of vaccination. The reporter consented to follow up. This case had been linked with the case US2021AMR153871, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR153871:Same reporter
Fatigue, Fever, Vomiting, Headache, injection Site pain and hot to the touch, Redness at Injection Site